Affected skin examination in psoriatic patients in the courseof Infliximab therapy (a morphologic analysis)

Abstract


The authors disclose the results of their own study carried out to examine the effect of Infliximab on the
pathomorphologic picture of affected skin in psoriatic patients in the course of therapy.

References

  1. Gudjonsson J.E., Elder J.T. Psoriasis: epidemiology. Clin. Dermatol. 2007; 25: 6: 535-546.
  2. Krueger J.G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann. Rheum. Dis. 2005; 64: 1130-1136.
  3. Griffits C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370: 263-271.
  4. Lowes M.A., Kikuchi T., Fuentes-Duculan J. et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. of Invest. Dermatol. 2008; 128: 1207-1211.
  5. Braun J., Sieper J. Owerview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert. Opin. Biol. Ther. 2003; 3: 1: 141-168.
  6. Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J.Am. Acad. Dermatol. 2004; 51: 4: 534-542.
  7. Кубанов А.А., Матушевская Ю.И. Опыт применения препарата инфликсимаб в лече- нии больных псориазом тяжелого течения. Вестн. дерматол. и венерол. 2008; 6: 81-86.
  8. Курдина М.И., Макаренко Л.А., Полянская А.А. Клинико-иммунологические параллели у больных псориазом на фоне лечения ин- фликсимабом. Клин. дерматол. и венерол. 2010; 2: 77-80.

Statistics

Views

Abstract - 522

PDF (Russian) - 219

PlumX

Article Metrics

Metrics Loading ...

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Katunina O.R., Znamenskaya L.F., Matushevskaya Y.I., Katunina O.R., Znamenskaya L.F., Matushevskaya Y.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies